Related Experiment Video
Updated: Aug 6, 2026
A Simple Red Blood Cell Lysis Method for the Establishment of B Lymphoblastoid Cell Lines
Published on: January 14, 2017
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies
Sunita J Shukla1, M Eileen Dolan
1Department of Human Genetics, University of Chicago, IL 60637, USA.
Abstract:
A long-term goal of pharmacogenomic research is the design of individualized therapy based on the genomic sequence of the patient in order to maximize response and minimize adverse drug reactions. Identifying genetic variants that predict drug response is challenging because drug responses reflect not only properties intrinsic to the target cell, but also host metabolic factors. One model that is currently being employed to study genotype-phenotype correlations involves the use of lymphoblastoid cell lines (LCLs). These cell lines have been used to identify genetic variation that influences response or susceptibility to cancer, radiation, transport, cytotoxicity, and variation in global gene expression. LCLs, particularly those derived from large pedigrees, are a valuable resource for identifying candidate genes and have potential for studies of many relevant phenotypes. This paper highlights studies that have utilized Centre d' Etude du Polymorphisme Humain (CEPH) and non-CEPH cell lines derived from humans for pharmacogenetic studies, and the advantages and disadvantages associated with this approach.
Insights
Pharmacogenomic research uses lymphoblastoid cell lines (LCLs) to link genetic variants to drug responses. This approach aids in developing personalized medicine by predicting treatment efficacy and reducing adverse drug reactions.
Area of Science:
- Pharmacogenomics
- Genetics
- Cell Biology
Background:
- Individualized therapy aims to maximize drug response and minimize adverse reactions based on patient genomic data.
- Drug response is influenced by both target cell properties and host metabolic factors, complicating genotype-phenotype correlation.
- Lymphoblastoid cell lines (LCLs) are a key model system for studying these genotype-phenotype relationships.
Purpose of the Study:
- To review the utility of human lymphoblastoid cell lines (LCLs) in pharmacogenetic research.
- To highlight studies using Centre d' Etude du Polymorphisme Humain (CEPH) and non-CEPH LCLs for pharmacogenetic investigations.
- To discuss the advantages and limitations of employing LCLs in pharmacogenetic studies.
Main Methods:
- Utilizing existing literature and study data on pharmacogenetic research involving LCLs.
- Analyzing studies that employed CEPH and non-CEPH LCLs derived from human subjects.
- Reviewing the application of LCLs in identifying genetic variants influencing drug response and susceptibility to various treatments.
Main Results:
- LCLs have been instrumental in identifying genetic variations impacting response to cancer treatments, radiation, and cytotoxic agents.
- These cell lines facilitate the study of global gene expression variations.
- LCLs, especially those from large pedigrees, serve as valuable resources for candidate gene identification.
Conclusions:
- Lymphoblastoid cell lines are a powerful tool for pharmacogenetic studies, enabling the identification of genetic determinants of drug response.
- The use of LCLs aids in understanding complex genotype-phenotype correlations relevant to personalized medicine.
- Careful consideration of the advantages and disadvantages of LCLs is crucial for successful pharmacogenetic research.
Related Concept Videos
01:16Cell Lines
01:29Pharmacogenomics: Identification of New Drug Targets